此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

研究炎症性肠道疾病中利用器官技术的组织修复 (ORGANOIDS)

2026年9月18日 更新者:Assistance Publique Hopitaux De Marseille

Inflammatory Bowel Diseases (IBD) are chronic inflammations of the gastrointestinal tract. Regardless of the etiology, a common trait of IBD pathogenesis is the inflammatory damage inflicted on the intestinal mucosa and the loss of intestinal epithelial barrier integrity. Therefore, understanding the mechanisms that govern IEC's capacity to maintain barrier function and to orchestrate mucosal healing is considered a major goal in translational research. The investigators are interested in understanding how the inflammatory environment present in the intestinal mucosa, of IBD patients influences epithelial cells capacity to govern repair. The complexities of the cytokine and metabolic milieu present in IBD patients render the study of the contribution of each cytokine, metabolite, and intracellular pathway extremely complicated. Therefore, most of the processes that govern tissue regeneration are studied with the use of mouse models that recapitulate one or multiple features of IBD and allow for genetical modifications of the gene and pathway of interest. While mouse models are uniquely suited to study the complex crosstalk between the immune system, the microbiota, and the intestinal epithelia, they introduce the important problem of species-specific differences, which can hamper the translational value of mouse studies.

To overcome these shortcomings, the investigators propose to explore the influence of cytokines and metabolites in digestive organoids derived from patients and controls. Importantly, it was demonstrated that gene expression and innate immune responses are altered in primary organoids derived from patients with IBD, including altered ability to proliferate, respond to cytokines, metabolic capacity, and efficiently form organoids suggesting that major differences between patient's and control's epithelial cell biology can be faithfully replicated in this system.

Given these premises, the investigators propose the following objectives:

Primary objective:

The main objective of this study is to establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases.

The investigators will explore this question both deriving organoids from clinical samples and exposing them to pro inflammatory cytokines and metabolites in vitro, as well as by analyzing repair responses from the aforementioned clinical samples ex vivo.

Secondary objective

The secondary goals of this study are:

- To compare organoids derived from: epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls in their capacity to mount a repair response in response to inflammatory cytokines or luminal metabolites.

Namely the investigators will evaluate the following parameters:

  • Their capacity to proliferate.
  • Their ability to survive treatment with pro-inflammatory cytokines
  • The activation of intracellular pathways associated with cell death.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.
  • To evaluate hallmarks of tissue repair in biopsies derived from epithelia in inflamed mucosa of IBD patients, epithelia in non-inflamed mucosa of IBD patients, and epithelia from the mucosa of non-IBD controls, and to correlate them to the levels of inflammatory cytokines, luminal metabolites and overall disease severity. Namely the investigators will evaluate the following parameters:
  • The abundance of proliferating cells.
  • The activation of intracellular pathways associated with cell death and survival.
  • Their overall metabolic activity.
  • The balance between stem and differentiated epithelial cell types.
  • The transcriptional activation of protective pathways such as those associated with proliferation, migration, differentiation and cell survival.

研究概览

研究类型

介入性

注册 (估计的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

学习地点

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

For IBD group the inclusion criteria will be:

  • Patients of either sex aged 18 years or older
  • Patient that have read the information form and signed consent
  • Patient covered with health insurance
  • Patients with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression.
  • Patients with colonic involvement of Crohn's disease or ulcerative colitis
  • Patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

For control group the inclusion criteria will be:

  • Patients of either sex aged 18 years or older
  • Patient that have read the information form and signed consent
  • Patient covered with health insurance
  • Patients undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

The non-inclusion criteria for IBD group will be:

  • Contraindication to the anaesthetic or colonoscopy procedure
  • Patients without colonic involvement of Crohn's disease or ulcerative colitis
  • Patients of Adults without legal capacity
  • Patients in Health and Social Establishments
  • Persons in emergency situations
  • Persons deprived of their liberty
  • Non-affiliated to a social security scheme
  • Absence or refusal of the informed consent

The non-inclusion criteria for control group will be:

  • IBD disease revealed during colonoscopy or gastrointestinal resection
  • Patient suffering from Immune-Mediated Inflammatory Diseases (IMIDs)
  • Contraindication to the anaesthetic or colonoscopy procedure
  • Patients of Adults without legal capacity
  • Patients in Health and Social Establishments
  • Persons in emergency situations
  • Persons deprived of their liberty
  • Non-affiliated to a social security scheme
  • Absence or refusal of the informed consent

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:基础科学
  • 分配:非随机化
  • 介入模型:并行分配
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
假比较器:Control group

Patients of either sex aged 18 years or older and undergoing a screening colonoscopy in the context of a family history of colonic neoplasia, follow-up of colonic polyps or functional intestinal disorders OR undergoing intestinal resection for intestinal neoplasia, occlusive syndrome or colostomy

Collection of 10 colonic biopsies in healthy tissue

Collection of a portion of healthy mucous membrane

实验性的:IBD group

Patients of either sex aged 18 years or older with Crohn's Disease or ulcerative colitis in accordance with accepted clinical, endoscopic, histological and/or radiologic criteria, regardless of the level, severity of the disease or duration of disease progression or patients undergoing a screening colonoscopy in the context of IBD disease follow-up OR undergoing intestinal resection for IBD disease aggravation

Collection of a portion of healthy mucous membrane

Collection of 10 colonic biopsies in IBD inflamed tissue

Collection of a portion of IBD inflamed mucous membrane

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Repair status of IBD patient's epithelial cells from inflamed mucosae
大体时间:From enrollmet to the end of following at 1 month

To establish that patient's epithelial cells from inflamed mucosae have decreased ability to repair the intestinal mucosa, as compared to epithelial cells from non-inflamed regions in the same patient, or to control subject with no inflammatory digestive diseases

From enrollmet to the end of following at 1 month

次要结果测量

结果测量
措施说明
大体时间
Evaluate the molecular mechanism involved in the reduced capacity of epithelial cells of IBD patients to repair intestinal mucosa
大体时间:From enrollment to the end of following at 1 month

Evaluation of:

  • The capacity epithelial cells of IBD patients to proliferate: ratio of Ki67+cells.
  • The ability of epithelial cells of IBD patients to survive treatment with pro-inflammatory cytokines: ratio between live and dead organoids.
  • The activation of intracellular pathways associated with cell death: relative quantification of biochemical activation of 1) apoptotic caspases,2) pyroptosis effectors (GSDMs),3) Necroptosis effectors (MLKL).
  • The balance between stem and differentiated epithelial cell types: the relative gene expression of the stemness associated genes LGR5, OLFM4, and the hallmark genes of differentiated cell types AQP8, MUC2, LYZ1, CHGA).
From enrollment to the end of following at 1 month
Genetically determine the involvement of cell death and protective pathways that reduce repair capacity in patients.
大体时间:From enrollment to the end of following at 1 month

After a genetically modify with CRISPR-CAS9 technology:

  • The capacity of modified epithelial cells of IBD patients to proliferate: ratio of Ki67+cells.
  • The ability of modified epithelial cells of IBD patients to survive treatment with pro-inflammatory cytokines: ratio between live and dead organoids.
  • The activation of intracellular pathways associated with cell death: relative quantification of biochemical activation of 1) apoptotic caspases,2) pyroptosis effectors (GSDMs),3) Necroptosis effectors (MLKL).
  • The balance between stem and differentiated epithelial cell types: the relative gene expression of the stemness associated genes LGR5, OLFM4, and the hallmark genes of differentiated cell types AQP8, MUC2, LYZ1, CHGA).
From enrollment to the end of following at 1 month
3. Explore the activation of molecular mechanisms identified in patient biopsies and correlate them with the inflammatory environment present in the patient's tissues
大体时间:From enrollment to the end of following at 1 month
  • Proliferation in FFPE biopsies and RNA from RNAlater fixed biopsies: Ki67 upregulation by immunohistochemistry (IHC), PCNA gene expression, Proliferation transcriptional signature by RNAseq etc…).
  • Cell death by biochemical analysis of cell death pathways by Western Blot (WB) and IHC in flash frozen biopsies: relative quantification of biochemical activation of 1) apoptotic caspases; 2) pyroptosis effectors (GSDMs); 3) Necroptosis effectors (MLKL).
  • Differentiation status of epithelial cells from DMSO conserved biopsies: staining of cell type markers by IHC, scRNAseq of dissociated epithelial cells.
  • The metabolic landscape of epithelial cells in flash frozen biopsies: the metabolome of the cells.
From enrollment to the end of following at 1 month

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2025年7月24日

初级完成 (估计的)

2027年3月24日

研究完成 (估计的)

2027年3月24日

研究注册日期

首次提交

2025年1月28日

首先提交符合 QC 标准的

2025年1月28日

首次发布 (实际的)

2025年2月3日

研究记录更新

最后更新发布 (实际的)

2026年9月21日

上次提交的符合 QC 标准的更新

2026年9月18日

最后验证

2026年9月1日

更多信息

与本研究相关的术语

其他研究编号

  • RCAPHM24_0062
  • 2024-A00510-47 (其他标识符:EUdraCT)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅